AzTrials
AzTrials

ADHDMiANCT07162831

Metacognitive Intervention in Children and Adolescents With ADHD - MiA Study

A study testing Mio-Training in people with ADHD, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of the MiA-Study is to address the current lack of effective treatment options to reduce cognitive and physical long-term problems in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Read more about this study

Who is it for?
Ages 8 to 16 years
Conditions the study is for
ADHD
What is being tested?
Mio-Training
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteSwitzerland
Study dates
1 Aug 2025to 31 Aug 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Informed consent as documented by signature (see Informed Consent Form) of participants and / or one parent / legal guardian
  • Age 8-16 years
  • A diagnosis of ADHD (mild, moderate or severe)
  • Intelligence >85 (WISC-V short form)
  • German or french speaking
  • Willingness to perform the assessments without the medication (the study visits will take place without ADHD medication)

Who cannot join

  • Any other instable neurological condition (e.g. epilepsy) that significantly impairs development
  • A severe psychiatric disease (e.g., eating disorder) or severe learning disability that significantly impairs development
  • Known or suspected non-compliance
  • Inability to follow the procedures of the study, e.g. due to language problems
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Regula Everts, Prof. Dr. phil. contact

+41 31 632 84 97

regula.everts@insel.ch

Saskia Salzmann, MSc contact

+41 31 664 59 84

saskia.salzmann@insel.ch

Switzerland1 site, 1 recruiting
  • Insespital, University Hospital Bern

    Bern, 3010

    Saskia Salzmann, MSc, +41 31 664 59 84, saskia.salzmann@insel.ch

    Recruiting

Other trials in Switzerland

About this study

The aim of the MiA-Study is to address the current lack of effective treatment options to reduce cognitive and physical long-term problems in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Through the use of the Mio-Training, cognitive development will be strengthened and metacognitive thinking and awareness will increase.

The MiA-Study is conducted additionally to the Mio-study to evaluate the effectiveness of the Mio-Training specifically within the ADHD population.

The Mio-Training for children and adolescence with ADHD includes a combination of cognitive and coordinative training tasks and prospective as well as retrospective metacognitive questions. In a randomized controlled trial, the Mio-Training will be analysed for its efficacy on metacognitive thinking and executive functions. In particular, the investigators are interested in factors that affect the efficacy of the training program such as compliance, age, sex or the severity of the ADHD. This study will give insight into the role of metacognition in cognitive performance and will foster the development of children and adolescents with ADHD in the long-term.

Read the detailed description

In the MiA-Study, the investigators investigate a newly developed Training program at the interface between neuropsychology and sports science - the Mio-Training - for its efficacy. The aim of the Mio-Training is to strengthen the cognitive development of children and adolescents with ADHD in the long-term. The Mio-Training contains a combination of cognitive and coordinative training tasks and metacognitive questions to promote knowledge and awareness of one's own thinking. In order to counteract the shortage of skilled workers and the increasing specialization of individual specialist areas, solutions are needed that can be implemented without a lot of staff. From today's perspective, there are hardly any trainings for children and adolescents that show long-term effects on cognitive development and can also be transferred to non-trained tasks in school and everyday life.

The investigators are testing the effectiveness of the Mio-Training in a randomized clinical trial (RCT) and expect a strengthening of metacognition and core cognitive functions (i.e. executive functions). The MiA-Study will provide information about the role of metacognition in cognitive performance and, ideally, provide evidence for a novel, interdisciplinary rehabilitation strategy for children and adolescents with ADHD.

Conditions
ADHD
Being tested
Mio-Training
Keywords
Metacognition, ADHD, Cognitive training, Children, Adolescents, Cognitive development
Medical subject headings
Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mio-TrainingBehavioural

    The Mio-Training aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and coordinative skills to strenghten cognitive development in children and adolescents with ADHD.

Study groups in NCT07162831
Study groupRoleWhat they receive
Training groupActive comparatorTraining with Mio-Training for 5 weeks, three times per week.
Receives: Behavioral: Mio-Training
Control groupNo interventionWaiting control group. Participants may use the Mio-Training after completion of the last follow-up assessment.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Junior Metacognitive Awareness Inventory (Jr.MAI)

    Total score of the Junior Metacognitive Awareness Inventory over the three timepoints (baseline, immediate followup \& 3-months follow-up). Raw values ranging 18-90. Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up

Secondary outcomes (8)
  1. Wechsler Intelligence Scale For Children: 5th Ed (WISC-V)

    Indices ranging from 0 to 155. Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period.

  2. Color-Word Interference Test (Delis-Kaplan Executive Function System; D-KEFS)

    Scaled Scores ranging from 1 to 19. Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period.

  3. Tower of Hanoi (D-KEFS)

    Scaled Scores ranging from 1 to 19. Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period.

  4. Verbal learning and memory test (VLMT)

    Percentile ranks ranging from 0-100. Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period.

  5. Pattern learning (Memory and Learning Test; Basic-MLT)

    Percentile ranks ranging from 0-100. Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period.

  6. Test Battery for Attention Assessment (TAP)

    T-scores ranging from 20 to 80 (M = 50, SD = 10). Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period.

  7. German Motor Performance Test (DMT)

    Percentile ranks ranging from 0-100. Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period.

  8. Behaviour Rating Inventory of Executive Function (BRIEF)

    T-scores ranging from 20 to 80 (M = 50, SD = 10). Higher scores mean better outcome.

    Measured: At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2025
  2. Study start1 Aug 2025
  3. Primary completion31 Aug 2027 (estimated)
  4. Study completion31 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07162831
Sponsor's protocol ID
BASEC2025-01189
Acronym
MiA
Status last verified
Sep 2025
First submitted
1 Sep 2025
Last updated
9 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data can be shared upon reasonable request

Questions about this trial

What is this clinical trial studying?

A study testing Mio-Training in people with ADHD, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Regula Everts, Prof. Dr. phil. (+41 31 632 84 97, regula.everts@insel.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Junior Metacognitive Awareness Inventory (Jr.MAI) (time frame: At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in